Nrf2-mediated metabolic reprogramming of tolerogenic dendritic cells is protective against aplastic anemia

Aplastic anemia (AA) is a rare disease characterized by immune-mediated suppression of bone marrow (BM) function resulting in progressive pancytopenia. Stem cell transplant and immunosuppressive therapies remain the major treatment choices for AA patients with limited benefit and undesired side effects. Here, we report for the first time the therapeutic utility of Nrf2-induced metabolically reprogrammed tolerogenic dendritic cells (ToIDCs) in the suppression of AA in mice. CDDO-DFPA-induced Nrf2 activation resulted in a ToIDC phenotype as evidenced by induction of IL-4, IL-10, and TGF-beta and suppression of TNF alpha, IFN-gamma, and IL-12 levels in Nrf2(+/+) but not Nrf2(-/-) DCs. Cellular metabolism holds the key to determining DC immunogenic or tolerogenic cell fate. Although immature and LPS-induced (mature) Nrf2(+/+) and Nrf2(-/-) DCs exhibited similar patterns of oxidative phosphorylation (OXPHOS) and glycolysis, only Nrf2(+/+) DCs partially restored OXPHOS and reduced glycolysis during CDDO-DFPA-induced Nrf2 activation. These results were further confirmed by altered glucose uptake and lactate production. We observed significantly enhanced HO-1 and reduced iNOS/NO production in Nrf2(+/+)- compared to Nrf2(-/-) DCs, suggesting Nrf2-dependent ToIDC induction is linked to suppression of the inhibitory effect of NO on OXPHOS. Furthermore, Nrf2(-/-) DCs demonstrated higher antigen-specific T cell proliferation. Lastly, ToIDC administration improved hematopoiesis and survival in AA murine model, with decreased Th17 and increased Treg cells. Concomitantly, immunohistochemical analysis of AA patient BM biopsies displayed higher DCs, T cells, and iNOS expression accompanied with lower Nrf2 and HO-1 expression when compared to normal subjects. These results provide new insight into the therapeutic utility of metabolically reprogrammed ToIDCs by CDDO-DFPA induced Nrf2 signaling in the treatment of AA.